Kane Biotech Inc.
KNE.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -392.30K | -441.00K | -251.90K | -849.00K | -773.60K |
| Total Depreciation and Amortization | 23.20K | 26.30K | 33.50K | 33.30K | 45.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.50K | 16.00K | -90.60K | 140.50K | 285.50K |
| Change in Net Operating Assets | -100.60K | -108.30K | -249.60K | -93.90K | 142.70K |
| Cash from Operations | -488.20K | -506.90K | -558.60K | -769.00K | -299.90K |
| Capital Expenditure | 0.00 | 0.00 | -- | -9.60K | -3.20K |
| Sale of Property, Plant, and Equipment | 0.00 | 43.60K | 6.40K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 402.50K |
| Other Investing Activities | -15.70K | -4.10K | -35.90K | -21.70K | -376.70K |
| Cash from Investing | -15.70K | 39.50K | -29.50K | -31.20K | 22.60K |
| Total Debt Issued | -27.50K | 0.00 | 1.00M | -- | -- |
| Total Debt Repaid | -17.50K | -21.40K | -113.20K | -154.70K | -154.30K |
| Issuance of Common Stock | 689.40K | 0.00 | 1.09M | 1.45M | 370.40K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 20.70K | -8.70K | -40.00K | -12.90K | -13.40K |
| Cash from Financing | 477.10K | -21.90K | 1.40M | 894.20K | 144.80K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.80K | -489.30K | 809.10K | 93.90K | -132.60K |